The venture capital company Asabys Partners, a member of Catalonia.health, leads €10 million extension of its oversubscribed €35 million Series C financing round through its Sabadell Asabys II fund, which joins a world-leading syndicate that includes Sofinnova Partners, Solar Eclipse, Gideon Strategic Partners, Polis, M&L Healthcare, and one of the world’s largest multinational life sciences corporations.
The new capital raise will further accelerate SafeHeal’s pivotal U.S. IDE study and support the planned commercial launch of Colovac® in the EU. Colovac is SafeHeal’s groundbreaking temporary endoluminal bypass device, designed to eliminate the need for a temporary stoma in most patients undergoing colorectal cancer resection, improving patient recovery, outcomes and quality of life.
As part of this financing round, Josep Lluis Sanfeliu, Managing Partner and co-founder of Asabys, will join SafeHeal’s Board of Directors. He commented: “Asabys is an ambitious and fast-growing investment firm committed to supporting world-class healthcare innovation across Europe and beyond. We are proud to join SafeHeal’s investor syndicate, reflecting our belief in both the outstanding team and the transformative impact of Colovac for patients facing colorectal cancer surgery. We look forward to working closely with SafeHeal’s management and our fellow investors to help bring this important technology to patients worldwide.”
Comments